Differentiating genomics companies.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 10657119.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
As the value of raw sequence data diminishes, genomics companies are evolving new competencies as providers of information, therapeutic products, or novel technology.
Medical subject headings
- Biotechnology
- Computational Biology
- Drug Industry
- Genome, Human
- Investments